{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:08:50Z","timestamp":1793578130124,"version":"4.5.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with thyroid cancer (TC) are commonly treated with radioactive iodine therapy (RIA) to prevent neoplastic transformation and the re-emergence of cancer cells. However, it has major side effects on blood cells. However, the degree of change in hematological parameters reported varies across studies. Therefore, the aim of this review was to assesses the mean differences in hematological parameters after RAI therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The relevant articles for this review were identified through extensive searches of databases and the Google search engine. The identified articles were subsequently selected using predetermined eligibility criteria. All relevant information from the screened articles was extracted. The pooled standardized mean differences (SMDs) of the parameters were assessed via a random effects model. The heterogeneity was determined by I<jats:sup>2<\/jats:sup> statistics test. Funnel plots and Egger\u2019s test were utilized to assess publication bias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 17 studies including 4,112 and 3,766 study participants before and after RAI therapy, respectively, were included. The pooled SMDs of the total leucocyte count (TLC) (*10<jats:sup>9<\/jats:sup>\/L) at one, three, six and 12 months and the last follow-up period were 2.39, 2.46, 5.84, 3.19, and 0.53, respectively. Changes in the TLC after one, three and six months of therapy were statistically significant. In terms of the absolute neutrophil count (ANC; *10<jats:sup>9<\/jats:sup>\/L) and absolute lymphocyte count (ALC; *10<jats:sup>9<\/jats:sup>\/L), the pooled SMDs at the last follow-up period were 6.32 and 7.37, respectively. In addition, statistically significant changes in the platelet count (PLT; *10<jats:sup>9<\/jats:sup>\/L) were observed at one, three, six and 12 months and at the last follow-up, with pooled SMDs of 7.01, 0.22, 2.63, 6.61, and 8.76, respectively. Furthermore, statistically significant changes in red blood cells (RBCs; *10<jats:sup>12<\/jats:sup>\/L) and hemoglobin (Hgb; g\/dl) were detected after three and six months of therapy, with pooled SMDs of -1.088 and 2.4, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>According to the current systematic review and meta-analysis, radioiodine therapy had a significant effect on hematological parameters. Thus, early screening and correction of hematological toxicity may be helpful for improving quality of life in thyroid cancer patients receiving radioiodine therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42024586449.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1562851","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:33:03Z","timestamp":1741951983000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of radioactive iodine therapy on hematological parameters in patients with thyroid cancer: systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Dereje Mengesha","family":"Berta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bisrat Birke","family":"Teketelew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negesse","family":"Cherie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mebratu","family":"Tamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zufan Yiheyis","family":"Abriham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiy","family":"Ayele Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amare Mekuanint","family":"Tarekegne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Chane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewudu","family":"Mulatie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muluken","family":"Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/toxics11060529","article-title":"Advances in antioxidant applications for combating 131I side effects in thyroid cancer treatment","volume":"11","author":"Yang","year":"2023","journal-title":"Toxics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003284","article-title":"Global burden of thyroid cancer in 2022: Incidence and mortality estimates from GLOBOCAN","volume":"137","author":"Lyu","year":"2024","journal-title":"Chin Med J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04090","article-title":"Assessing and projecting the global burden of thyroid cancer, 1990\u20132030: Analysis of the Global Burden of Disease Study","volume":"14","author":"Zhao","year":"2024","journal-title":"J Global Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-024-03688-5","article-title":"Prognostic role and characteristics of the indeterminate response in differentiated thyroid cancer: a systematic review","volume":"84","author":"Bellini","year":"2024","journal-title":"Endocrine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/chemosensors12110229","article-title":"Conventional and emerging diagnostic approaches for differentiated thyroid carcinoma","volume":"12","author":"Kristollari","year":"2024","journal-title":"Chemosensors"},{"key":"B7","doi-asserted-by":"publisher","first-page":"188928","DOI":"10.1016\/j.bbcan.2023.188928","article-title":"Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochim Biophys Acta (BBA)-Reviews Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00448-z","article-title":"Current practice in patients with differentiated thyroid cancer","volume":"17","author":"Schlumberger","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2024.05.002","article-title":"Radioactive iodine therapy in differentiated thyroid cancer: an update on dose recommendations and risk of secondary primary Malignancies","volume-title":"Seminars in Nuclear Medicine","author":"Nguyen","year":""},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0484","article-title":"Thyroid cancer: risk-stratified management and individualized therapy","volume":"22","author":"Raue","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"101687","DOI":"10.1016\/j.beem.2022.101687","article-title":"Differentiated thyroid carcinoma: an update","volume":"37","author":"van Houten","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0883-1","article-title":"Guidelines for radioiodine therapy of differentiated thyroid cancer","volume":"35","author":"Luster","year":"2008","journal-title":"Eur J Nucl Med Mol imaging"},{"key":"B13","doi-asserted-by":"publisher","first-page":"23349","DOI":"10.1038\/s41598-024-72002-0","article-title":"Assessing radioiodine therapy long-term outcomes in differentiated thyroid cancer using nomograms","volume":"14","author":"Alshwayyat","year":"2024","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000132","article-title":"Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma","volume":"35","author":"Fard-Esfahani","year":"2014","journal-title":"Nucl Med Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e26595","DOI":"10.1002\/pbc.v64.11","article-title":"Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer","volume":"64","author":"Albano","year":"2017","journal-title":"Pediatr Blood cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0094","article-title":"Complications of radioactive iodine treatment of thyroid carcinoma","volume":"8","author":"Lee","year":"2010","journal-title":"J Natl Compr Cancer Network"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0235","article-title":"Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin","volume":"22","author":"Klubo-Gwiezdzinska","year":"2012","journal-title":"Thyroid"},{"key":"B18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s42000-023-00479-x","article-title":"The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer","volume":"22","author":"Demir","year":"2023","journal-title":"Hormones"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2015.499","article-title":"Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients","volume":"3","author":"Monzen","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.473","article-title":"The hematologist and radiation casualties","volume":"2003","author":"Dainiak","year":"2003","journal-title":"ASH Educ Program Book"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14925","article-title":"Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study","volume":"99","author":"Boucai","year":"2023","journal-title":"Clin Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000432397","article-title":"Radioiodine treatment and thyroid hormone suppression therapy for differentiated thyroid carcinoma: adverse effects support the trend toward less aggressive treatment for low-risk patients","volume":"4","author":"Hesselink","year":"2015","journal-title":"Eur Thyroid J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3390\/cancers14102505","article-title":"Radioactive iodine treatment for thyroid cancer patients increases the risk of long-term gastrointestinal disorders: A nationwide population-based cohort analysis","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4149\/BLL_2019_048","article-title":"Beneficial effects of vitamin E on radioiodine induced gastrointestinal damage: an experimental and pathomorphological study","volume":"120","author":"Yumusak","year":"2019","journal-title":"Bratislava Med Journal\/Bratislavske Lekarske Listy"},{"key":"B25","first-page":"40","article-title":"Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study","volume":"16","author":"Aktoz","year":"2012","journal-title":"Hippokratia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(83)90173-X","article-title":"Effect of 131I on the anemia of hyperthyroidism","volume":"36","author":"Perlman","year":"1983","journal-title":"J Chronic Diseases"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000067147","article-title":"Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment","volume":"63","author":"Harrison","year":"2002","journal-title":"Oncology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1944-5","article-title":"The effect of gamma radiation on the lipid profile of irradiated red blood cells","volume":"93","author":"Maia","year":"2014","journal-title":"Ann hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S403045","article-title":"Blood profiles in the prediction of radioiodine refractory papillary thyroid cancer: A case\u2013control study","volume":"16","author":"Liu","year":"2023","journal-title":"J Multidiscip Healthcare"},{"key":"B30","first-page":"67","article-title":"Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients","volume":"44","author":"Siegel","year":"2003","journal-title":"J Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2013_074","article-title":"Radioiodine therapy accelerates apoptosis in peripheral blood lymphocytes of patients with differentiated thyroid cancer","author":"Vrndic","year":"2013"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.164814","article-title":"DNA damage in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy","volume":"57","author":"Eberlein","year":"2016","journal-title":"J Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mrgentox.2009.02.004","article-title":"Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis","volume":"675","author":"Joseph","year":"2009","journal-title":"Mutat Research\/Genetic Toxicol Environ Mutagenesis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.55981\/aij.2024.1381","article-title":"The effect of I-131 treatment on complete blood count","volume":"50","author":"Sahutoglu","year":"2024","journal-title":"Atom Indonesia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ20-0242","article-title":"Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment","volume":"67","author":"Yi","year":"2020","journal-title":"Endocrine J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.929590","article-title":"Effect of 131I therapy on complete blood count in patients with differentiated thyroid cancer","volume":"27","author":"Rui","year":"2021","journal-title":"Med Sci monitor"},{"key":"B37","first-page":"306","article-title":"Assessment of long-term hematologic effects in differentiated thyroid cancer patients treated with radioactive iodine","volume":"38","author":"S\u00f6nmez","year":"2021","journal-title":"Turkish J Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Systematic Rev"},{"key":"B39","article-title":"Systematic reviews of etiology and risk","volume-title":"Joanna Briggs Institute reviewer\u2019s manual","author":"Moola","year":"2017"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3544","article-title":"Effects of dosimetrically guided I-131 therapy on hematopoiesis in patients with differentiated thyroid cancer","volume":"101","author":"Bikas","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1515\/med-2016-0017","article-title":"Blood cells in thyroid cancer patients: a possible influence of apoptosis","volume":"11","author":"Vrndic","year":"2016","journal-title":"Open Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2019.1665206","article-title":"The effect of radioiodine treatment on the diseased thyroid gland","volume":"95","author":"Riley","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021398","article-title":"Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy","volume":"99","author":"Dong","year":"2020","journal-title":"Medicine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s00259-009-1303-x","article-title":"Dosimetry-guided high-activity 131 I therapy in patients with advanced differentiated thyroid carcinoma: initial experience","volume":"37","author":"Verburg","year":"2010","journal-title":"Eur J Nucl Med Mol imaging"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3233\/CH-190717","article-title":"Hemorheology and oxidative stress in patients with differentiated thyroid cancer following I-131 ablation\/metastasis treatment","volume":"74","author":"Sengoz","year":"2020","journal-title":"Clin Hemorheol Microcirculation"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0423","article-title":"Bone-marrow suppression in elderly patients following empiric radioiodine therapy: real-life data","volume":"29","author":"Duskin-Bitan","year":"2019","journal-title":"Thyroid"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e4451","DOI":"10.1097\/MD.0000000000004451","article-title":"Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer","volume":"95","author":"Hu","year":"2016","journal-title":"Medicine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0430","article-title":"Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation","volume":"19","author":"Molinaro","year":"2009","journal-title":"Thyroid"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2017.09.019","article-title":"Aggressive differentiated thyroid cancer","volume":"44","author":"Janjua","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"B50","volume-title":"Radioactive Iodine Therapy for Thyroid Malignancies","author":"Manzil","year":"2024"},{"key":"B51","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41420-024-02157-2","article-title":"High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discovery"},{"key":"B52","article-title":"Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer","volume":"45","author":"de Keizer","year":"2004","journal-title":"J Nucl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4158\/EP13172.OR","article-title":"Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer","volume":"20","author":"Padovani","year":"2014","journal-title":"Endocrine Pract"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2124","article-title":"Bone marrow function after 131I therapy in patients with differentiated thyroid carcinoma","volume":"100","author":"Prinsen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","article-title":"Radyoaktif iyot tedavisi alan tiroid kanserli hastalarda tam kan say\u0131m\u0131 de\u011fi\u015fiklikleri","author":"S\u00f6nmez","year":"2010"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035339","article-title":"Assessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort","volume":"102","author":"Soyluoglu","year":"2023","journal-title":"Medicine"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1562851\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:33:09Z","timestamp":1741951989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1562851\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":56,"alternative-id":["10.3389\/fendo.2025.1562851"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1562851","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"article-number":"1562851"}}